In their work, Qiu showed that targeted biopsies provided by the combinatorial PET/CT image of PSMA and GRPR PET/CT tracers significantly improved the diagnosis of prostate cancer patients (Qiu et al. 2022). This evidence concerns the gene FOLH1 and prostate carcinoma.